RapamycinNCT05836025
Effect of Rapamycin in Ovarian Aging
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 18, 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 3 words
- Trial completed
- Study completion date changed from estimate of Sep 2026 to Oct 21, 2025
- Secondary endpoints: 4 to 3
- Site details revised
- Minor Primary completion date changed from estimate of Oct 2025 to Oct 21, 2025v6
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date: Apr 2025 to Oct 2025
- Study completion date: Dec 2025 to Sep 2026
- Site details revised
- Notable Primary completion date: May 2024 to Apr 2025
- Study completion date: Dec 2024 to Dec 2025
- Notable Eligibility criteria expanded, about 6 words
- Primary completion date: May 31, 2024 to May 2024
- Start date changed from estimate of Jun 2023 to Jun 1, 2023
- Secondary endpoints revised (4)
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Apr 2023 to Jun 2023
- Primary completion date: Apr 2024 to May 31, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Measure of Ovarian Reserve
Timeframe: Baseline, 12 months post-intervention
Secondary (3)
Antral Follicle Counts (AFC)
Estradiol (E2) Level
FSH Level
Arms and interventions
RapamycinExperimental
Participants randomized to the treatment arm will receive 5mg/week of rapamycin orally, for 12 weeks (3 months).
PlaceboPlacebo comparator
Participants randomized to the placebo arm will receive placebo orally, for 12 weeks (3 months).
Drugs: Rapamycin
Other: Placebo
Sites
1 site in 1 country
- Columbia University Irving Medical Center / NewYork-Presbyterian HospitalNew York, New York, United States